Efficacy of Filgotinib in Patients with Ulcerative Colitis by Line of Therapy in the Phase 2b/3 SELECTION Trial.

"Conflict of Interest AH, AO, CR, ES and VT are employees and shareholders of Galapagos. BGF reports grants and personal fees from AbbVie, Amgen, AstraZeneca, BMS, Janssen Biotech/Centocor, J&J/Janssen, Pfizer, Receptos and Takeda; and personal fees from Ablynx, ActoGeniX, AdMIRx, Inc., Akebia Therapeutics, Inc., Allergan, Atlantic Pharma, Avaxia Biologics, Inc., Avir Pharma, Baxter Healthcare Corporation, Biogen Idec, BiomX Israel, Boehringer Ingelheim, Boston Pharmaceuticals, Calypso Biotech, Celgene, Elan/Biogen, enGene, Ferring, Galapagos, Genentech/Roche, gIcare Pharma, Gilead, Given Imaging, Gossamer Pharma, GSK, Inception IBD, Inc., Ironwood, Japan Tobacco Company, Kyowa Hakko Kirin Co. Ltd., Lexicon, Lilly, Lycera Biotech, MSD, Mesoblast, Millennium, Nestlé, Nextbiotix, Novartis, Novo Nordisk, Par’Immune, Progenity, Prometheus Therapeutics & Diagnostics, Protagonist, Qu Biologics, Salix, Shire, Sienna Biologics, Sigmoid Pharma, Synergy Pharma, Teva Pharmaceuticals, TiGenix, Tillotts, UCB, Vertex, VHsquared, Vivelix Pharmaceuticals, Wyeth, Zealand and Zyngenia outside the submitted work. ID reports personal fees from Abbott, AbbVie, Arena, Athos, Cambridge Healthcare, Celgene/BMS, Celltrion, Ferring, Falk Pharma, Food Industries Organization, Gilead, Galapagos, Iterative Scopes, Integra Holdings, Janssen, Neopharm, Pfizer, Rafa Laboratories, Roche/Genentech, Sangamo, Sublimity, Nestle, Takeda and Wildbio; and speaking and teaching fees from AbbVie, Altman, Celltrion, Celgene/BMS, Ferring, Falk Pharma, Janssen, Neopharm, Pfizer, Roche/Genentech and Takeda. JH is an employee and shareholder of Gilead Sciences. LPB has received personal fees from AbbVie, Alimentiv, Alma Bio Therapeutics, Amgen, Applied Molecular Transport, Arena, Biogen, BMS, Boston Pharma, Celltrion, CONNECT Biopharm, Cytoki Pharma, Diaceutics, Enthera, Ferring, Fresenius Kabi, Galapagos, Genentech, Gilead, Gossamer Bio, GSK, HAC-Pharma, IAG Image Analysis, InDex Pharmaceuticals, Inotrem, Janssen, Lilly, Medac, Mopac, Morphic, MSD, Mylan, Norgine, Novartis, OM Pharma, ONO Pharma, OSE Immunotherapeutics, Pandion Therapeutics, Pfizer, Prometheus, Protagonist, Roche, Sandoz, Sublimity Therapeutics, Takeda, Theravance, Thermo Fisher, Tillotts, Viatris and Vifor; and speaking fees from AbbVie, Amgen, Arena, Biogen, Celltrion, Ferring, Galapagos, Genentech, Gilead, Janssen, Lilly, Medac, MSD, Pfizer, Sandoz, Takeda, Tillots, Viatris and Vifor. TH reports grants from Otsuka Holdings; grants and personal fees from AbbVie GK, JIMRO, Kyorin, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Takeda Pharmaceutical and Zeria Pharmaceutical; and personal fees from Aspen Japan K.K, BMS, Celltrion, EA Pharma, Lilly, Ferring, Gilead, Janssen, Kissei Pharmaceutical, Nichi-Iko Pharmaceutical, Nippon Kayaku and Pfizer outside the submitted work."

"Funding This work was supported by Galapagos NV [Mechelen, Belgium], which was a collaborator for the SELECTION study. SELECTION was sponsored by Gilead Sciences, Inc."